Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 23

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 23
---
 structure and improve profitability 4 April 24, 2025 Announced appointment of independent director Louis Silverman; Wei Jiang named to temporary role of Chief of APAC Strategy 1 3 4 Significant action on management changes, focus on profitability, and reestablishing growth March 17, 2025 Appointed Deborah Andrews CFO Realigned leadership structure 2 3 February 11, 2025 Reported Q4 2024 and FY 2024 results. Decline in valuation reflects a reset to lower go-forward growth profile. 2 Source: Company filings, FactSet and Wall Street research. Note: Market data as of September 11, 2025. 5 August 4, 2025 Entered into Alcon merger agreement 5 Headwinds create downside risk for the standalone company. STAAR’s stock was trading at $18.49 prior to the Alcon agreement. EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

Board’s decision to respond to Alcon’s outreach was based on good governance and thoughtful evaluation of available options to maximize value With new CEO, CFO, and realigned management team in place, STAAR withdrew its 2025 financial guidance in May 2025 and carefully considered standalone business prospects, STAAR’s expected long-term growth rate, and best path to maximizing stockholder value. Improved expense profile expected to drive profitability, but slower top-line growth profile has reset value expectations compared to historical levels. Progress with planned reduction of channel inventory in China and alignment with in-market procedure volume, but China challenges still remain. Despite management efforts, headwinds from standalone risks likely to depress valuation for the foreseeable future. The Board and its Committees held 20+ meetings between January 1, 2025 – August 4, 2025 The Board considered various risk-adjusted growth scenarios and the implications for standalone value creation The Board analyzed the industry landscape, the universe of potential buyers, and alternatives on multiple occasions The Board mitigated the risks from conducting a full pre-signing sales process by negotiating a favorable “window shop” The Board assessed splitting the business, but did not believe the value creation opportunity outweighed the complexity and cost EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

Merger agreement terms were aggressively negotiated by STAAR’s Board to protect premium value in hand